ELICIO THERAPEUTICS INC

Share price plummets after Elicio’s AMPLIFY‑7P trial misses the primary endpoint, but the company’s refined Phase 3 strategy and strong safety profile offer a potential comeback.

Elicio Therapeutics Inc is a biopharmaceutical company with a bold mission to revolutionize cancer and infectious disease treatment, but its financial volatility and market competition raise questions about its long-term prospects.